Table 1. Characteristics of subjects in model group and validation group.
| Parameters | Model group (n = 182) | Validation group (n = 182) | Test value | P value |
|---|---|---|---|---|
| Male (n,%) | 148 (81.3) | 150 (82.4) | 0.07 | 0.786# |
| Age (years) | 33.8 ± 9.1 | 35.0 ± 9.9 | −1.246 | 0.213 |
| BMI (kg/m2) | 23.3 ± 4.2 | 22.6 ± 3.4 | 1.793 | 0.074 |
| WC (cm) | 72.7 ± 12.5 | 69.4 ± 11.6 | 2.616 | 0.009 |
| ALT (U/L) | 73 (39, 150) | 71 (39, 159) | 0.524 | 0.946* |
| AST (U/L) | 50 (34, 84) | 51 (36, 80) | 0.472 | 0.979* |
| γ-GT (U/L) | 55 (30, 115) | 54 (30, 107) | 0.891 | 0.405* |
| Log DNA (copies/ml) | 4.7 ± 2.8 | 4.6 ± 2.8 | 0.277 | 0.782 |
| Albumin (G/L) | 43.8 ± 4.7 | 44.7 ± 4.5 | −1.702 | 0.09 |
| WBC (109/l) | 5.7 ± 1.6 | 5.7 ± 1.4 | 0.136 | 0.892 |
| HGB (G/L) | 145.0 ± 16.0 | 144.0 ± 15.7 | 0.475 | 0.635 |
| PLT (109/l) | 183.9 ± 55.1 | 184.7 ± 53.8 | −0.145 | 0.885 |
| PT (second) | 12.4 ± 1.3 | 12.4 ± 1.3 | −0.322 | 0.748 |
| SUA (mmol/l) | 350.5 ± 93.2 | 351.7 ± 100.8 | −0.119 | 0.906 |
| FPG (mmol/l) | 4.8 ± 0.9 | 4.8 ± 1.1 | −0.091 | 0.923 |
| TC (mmol/l) | 4.5 ± 1.0 | 4.4 ± 1.0 | 0.576 | 0.565 |
| TG (mmol/l) | 1.3 ± 0.9 | 1.3 ± 0.8 | −0.118 | 0.906 |
| HDL (mmol/l) | 1.4 ± 0.4 | 1.3 ± 0.4 | 1.922 | 0.055 |
| LDL (mmol/l) | 2.4 ± 0.7 | 2.4 ± 0.8 | −0.233 | 0.816 |
| Inflammation Grade 1 (n,%) | 8 (4.4) | 10 (5.5) | 2.18 | 0.535* |
| Inflammation Grade 2 (n,%) | 80 (44.0) | 92 (50.5) | ||
| Inflammation Grade 3 (n,%) | 69 (37.9) | 59 (32.4) | ||
| Inflammation Grade 4 (n,%) | 25 (13.7) | 21 (11.5) | ||
| Fibrosis Stage 1 (n,%) | 27 (14.8) | 28 (15.4) | 2.95 | 0.399* |
| Fibrosis Stage 2 (n,%) | 72 (39.6) | 69 (37.9) | ||
| Fibrosis Stage 3 (n,%) | 40 (22.0) | 52 (28.6) | ||
| Fibrosis Stage 4 (n,%) | 43 (23.6) | 33 (18.1) | ||
| Steatosis grade0 (n,%) | 123 (67.6) | 123 (67.6) | 0.56 | 0.906* |
| Steatosis grade1 (n,%) | 44 (24.2) | 47 (25.8) | ||
| Steatosis grade2 (n,%) | 9 (4.9) | 8 (4.4) | ||
| Steatosis grade3 (n,%) | 6 (3.3) | 4 (2.2) | ||
| Fatty liver diagnosed by US (n,%) | 30 (16.5) | 34 (18.7) | 0.3 | 0.582# |
| Antiviral therapy (n,%) | 40 (22.0) | 32 (17.6) | 1.11 | 0.293# |
| HBeAg positive (n,%) | 124 (68.1) | 114 (62.6) | 1.21 | 0.271# |
| HBV DNA positive (n,%) | 143 (78.6) | 141 (77.5) | 0.06 | 0.80# |
*Kruskal-Wallis H test.
#Chi-square test. Hepatic steatosis were diagnosed by liver biopsy.
SUA, Serum uric acid; FPG, Fasting plasma glucose; TC, Total cholesterol; TG, Triglyceride; HDL, high-density lipoprotein cholestero; LDL, low-density lipoprotein cholestero; ALT, Alanine aminotransferase; AST, Aspartate aminotransferase; γ-GT, γ-glutamyl transferase; BMI, body mass index; WC, waist circumference; WBC, white blood cell; PLT, blood platelet; HGB, hemoglobin; PT, Prothrombin time.
Continuous data were expressed as mean ± SD or median (uartile range) depending on the normality of the data. Categorical variables were expressed as proportions.